Salah-Eddin Al-Batran

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology · 2018 · 503 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · The Lancet Oncology · 2023 · 339 citations

Medicine, Oncology, Pharmacology +16

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg et al. · New England Journal of Medicine · 2025 · 223 citations

Medicine, Oncology, Perioperative Medicine +14

Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

Salah-Eddin Al-Batran, Sylvie Lorenzen, Peter Thuss‐Patience et al. · Journal of Clinical Oncology · 2022 · 96 citations

Medicine, Oncology, Surgery +16

Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial

Georg Martin Haag, Christoph Springfeld, Barbara Grün et al. · European Journal of Cancer · 2022 · 95 citations

Medicine, Oncology, Chemotherapy +11